Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Pre-Mkt 08-05 05:37:53 EDT

9.17

+0.27

+3.03%

盘前9.40

+0.23+2.51%

05:02 EDT

High9.28	Low8.93	Vol1.71M
Open9.02	D1 Closing8.90	Amplitude3.88%
Mkt Cap1.55B	Tradable Cap1.18B	Total Shares168.65M
T/O15.65M	T/O Rate1.32%	Tradable Shares129.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":9.17,"timestamp":1785873600000,"preClose":8.9,"halted":0,"volume":1708608,"hourTrading":{"tag":"盘前","latestPrice":9.4,"preClose":9.17,"latestTime":"05:02 EDT","volume":1737,"amount":16374.909177,"timestamp":1785920564525,"change":0.23,"changeRate":0.025082,"amplitude":0.029444},"delay":0,"changeRate":0.030337078651685345,"floatShares":129000000,"shares":168651974,"eps":-3.140006,"marketStatus":"Pre-Mkt","change":0.27,"latestTime":"08-05 05:37:53 EDT","open":9.02,"high":9.275,"low":8.93,"amount":15648445.268544,"amplitude":0.038764,"askPrice":9.81,"askSize":100,"bidPrice":8.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.140006,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1785936600000},"marketStatusCode":1,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":9.17,"preHourTrading":{"tag":"盘前","latestPrice":9.4,"preClose":9.17,"latestTime":"05:02 EDT","volume":1737,"amount":16374.909177,"timestamp":1785920564525,"change":0.23,"changeRate":0.025082,"amplitude":0.029444},"postHourTrading":{"tag":"盘后","latestPrice":9.15,"preClose":9.17,"latestTime":"19:55 EDT","volume":38004,"amount":348600.61,"timestamp":1785887734280,"change":-0.02,"changeRate":-0.002181,"amplitude":0.012748},"volumeRatio":1.3411020502146405,"impliedVol":0.6704,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2656958300","title":"Vir Biotechnology Inc Expected to Post Earnings of 33 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958300","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656958300?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:39","pubTimestamp":1785796787,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc <VIR.OQ> expected to post earnings of33cents a share - Earnings PreviewVir Biotechnology IncVIR.OQVIR.Ois expected to  show a rise in quarterly revenue when it reports  results o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402OZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VIR","BK4139","BK4535","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184050798","title":"Earning Preview: Vir Biotechnology, Inc. Q2 revenue expected to increase by 7,852%, institutional views are bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1184050798","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184050798?lang=en_us&edition=fundamental","pubTime":"2026-07-30 00:49","pubTimestamp":1785343773,"startTime":"0","endTime":"0","summary":"Abstract Vir Biotechnology, Inc. will report its second-quarter results on August 5, 2026, Post Market, with consensus pointing to a sharp rebound in revenue and a return to positive per-share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Earning Preview: Vir Biotechnology, Inc. Q2 revenue expected to increase by 7,852%, institutional views are bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653808255","title":"Vir Biotechnology Names Brent Sabatini Interim Principal Financial Officer as CFO Exits","url":"https://stock-news.laohu8.com/highlight/detail?id=2653808255","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653808255?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896253,"startTime":"0","endTime":"0","summary":"Vir Biotechnology names Brent Sabatini interim principal financial officer as CFO exitsVir Biotechnology named Brent Sabatini interim principal financial officer effective July 23.Jason O'Byrne will d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL6LBDpS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","BK4139","VIR","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082326","title":"Vir Biotechnology - Appoints Brent Sabatini as Interim Principal Financial Officer Effective July 23","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653082326?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA3K4MWJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","VIR","BK4535","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082320","title":"Vir Biotechnology - Jason O’byrne to Leave Vir Biotechnology, Remains Through August 3 for Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082320","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653082320?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA3K4MWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4139","BK4568","VIR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653082309","title":"Vir Biotechnology Announces Chief Financial Officer Transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2653082309","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653082309?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:30","pubTimestamp":1784896200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA3K4MWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","VIR","BK4535","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653174798","title":"Vir Biotechnology Schedules Conference Call on Second-quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2653174798","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653174798?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:07","pubTimestamp":1784750862,"startTime":"0","endTime":"0","summary":"Vir Biotechnology schedules conference call on second-quarter 2026 resultsVir Biotechnology will host a conference call on Aug. 5 to discuss second-quarter results ended June 30, 2026, with a corporat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL6ycCPy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","VIR","BK4535","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648763994","title":"Brii Biosciences Says Arbitration with Vir Clouds Future of Elebsiran Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2648763994","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648763994?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:56","pubTimestamp":1783033010,"startTime":"0","endTime":"0","summary":"Brii Biosciences says arbitration with Vir clouds future of elebsiran programBrii flagged ongoing arbitration with Vir Biotechnology that has made the future of its elebsiran hepatitis B program uncer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL1dwW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK4535","BK4568","BK1161","BK4139","BK1574","VIR","BK4585","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644770827","title":"Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?","url":"https://stock-news.laohu8.com/highlight/detail?id=2644770827","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644770827?lang=en_us&edition=fundamental","pubTime":"2026-06-18 13:29","pubTimestamp":1781760563,"startTime":"0","endTime":"0","summary":"In June 2026, Vir Biotechnology’s Board expanded from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director and Chair of the Audit Committee, effective June 9, 2026.\nCoughlin’s audit leadership experience and history guiding biotech companies through regulatory and commercial inflection points could influence how investors view Vir’s governance and execution capabilities.\nWe’ll now examine how adding an experienced audit committee chair like Coughlin may shape...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/is-vir-biotechnology-vir-quietly-recasting-its-governance-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/is-vir-biotechnology-vir-quietly-recasting-its-governance-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VIR","BK4585","BK4139","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642276284","title":"Vir Biotechnology Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2642276284","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642276284?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:40","pubTimestamp":1781181600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 08:40 ET (12:40 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","VIR","BK4568","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642865292","title":"Vir Biotechnology Inc : Morgan Stanley  Raises Target Price to $27.00 From $23.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2642865292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642865292?lang=en_us&edition=fundamental","pubTime":"2026-06-11 18:53","pubTimestamp":1781175205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nAZN4T1T1U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4585","BK4568","BK4139","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642047596","title":"Vir Biotechnology names Timothy Coughlin to board, taps him as audit committee chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2642047596","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642047596?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:05","pubTimestamp":1781121922,"startTime":"0","endTime":"0","summary":"Vir Biotechnology appointed Timothy Coughlin to its board, effective June 9, 2026.He previously served as CFO of Neurocrine Biosciences, helping shift it from clinical-stage to a commercial pharmaceutical company.Earlier roles include vice president of financial services at Catholic Health Initiatives, with prior experience at Ernst & Young.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL5yxn0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU0154245673.USD","LU2065171402.SGD","LU0109394709.USD","BK4585","LU0889565916.HKD","LU0154245756.USD","LU2324357040.USD","BK4535","VIR","BK4568","LU0823416689.USD","LU0320765992.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642155475","title":"Vir Biotechnology Announces Appointment of Timothy Coughlin to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642155475","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642155475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:05","pubTimestamp":1781121901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA9DQRJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4568","BK4535","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640290027","title":"Vir Biotechnology Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2640290027","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640290027?lang=en_us&edition=fundamental","pubTime":"2026-06-03 22:30","pubTimestamp":1780497000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 10:30 ET (14:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4535","BK4139","BK4585","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640392607","title":"Vir director Janet Napolitano disposes of 3,200 Vir Biotechnology shares for $30,240","url":"https://stock-news.laohu8.com/highlight/detail?id=2640392607","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640392607?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:35","pubTimestamp":1780436150,"startTime":"0","endTime":"0","summary":"Vir Biotechnology director Janet Napolitano sold 3,200 common shares on June 1, 2026 at USD 9.45.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL21zPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","BK4568","BK4139","VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492606","title":"Vir Biotechnology SVP, Chief Accounting Officer Brent Sabatini sells 379 shares for $3,581.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492606","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640492606?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:32","pubTimestamp":1780435941,"startTime":"0","endTime":"0","summary":"Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini sold 379 common shares on June 1, 2026.Shares sold at $9.45; holdings fell to 61,902 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL9mlHWc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vir Biotechnology SVP, Chief Accounting Officer Brent Sabatini sells 379 shares for $3,581.55","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VIR","BK4535","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638469428","title":"H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638469428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638469428?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:47","pubTimestamp":1779979664,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology today and set a price target of $20.00. Trucchio covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638569687","title":"Vir Biotechnology shareholders elect three directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638569687","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638569687?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:06","pubTimestamp":1779973599,"startTime":"0","endTime":"0","summary":"Vir Biotechnology held its annual shareholder meeting on May 26, 2026.Shareholders selected three Class I directors to serve through the 2029 annual meeting.Shareholders backed a non-binding advisory resolution on executive pay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL3RFdkt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4585","BK4139","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638068639","title":"Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638068639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638068639?lang=en_us&edition=fundamental","pubTime":"2026-05-27 21:50","pubTimestamp":1779889808,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-anaptysbio-anab-geovax-labs-govx-and-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-anaptysbio-anab-geovax-labs-govx-and-vir-biotechnology-vir-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4568","BK4588","BK4585","FFTY","GOVX","BK4583","BK4137","BK4581","LU0029874061.USD","XLV","XBI","ANAB","HCSG","VIR","LU0128526141.USD","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638585215","title":"Assessing Vir Biotechnology (VIR) Valuation After Hepatitis Delta Data Update And Astellas Oncology Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2638585215","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638585215?lang=en_us&edition=fundamental","pubTime":"2026-05-25 08:20","pubTimestamp":1779668429,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) is back in focus after announcing it will present Phase 2 SOLSTICE trial data for its tobevibart and elebsiran combination in chronic hepatitis delta at the upcoming EASL Congress 2026.\nSee our latest analysis for Vir Biotechnology.\nThe latest SOLSTICE update comes after a period of strong trading interest, with the share price at $9.19, a 90 day share price return of 23.69% and a 1 year total shareholder return of 104.22%. However, multi year total shareholder returns...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/assessing-vir-biotechnology-vir-valuation-after-hepatitis-de","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/assessing-vir-biotechnology-vir-valuation-after-hepatitis-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VIR","BK4585","BK4139","BK4568","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":-0.0867},{"period":"3month","weight":-0.1088},{"period":"6month","weight":0.3251},{"period":"1year","weight":0.798},{"period":"ytd","weight":0.5207}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.428571,"avgChangeRate":0.063735},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.106207},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.055273},{"month":5,"riseRate":0.571429,"avgChangeRate":0.040281},{"month":6,"riseRate":0.571429,"avgChangeRate":0.026907},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.059573},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.01533},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}